New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
07:15 EDTPCYCPharmacyclics price target raised to $96 from $83 at Piper Jaffray
Piper Jaffray said Pharmacyclics confirmed the filing for ibrutinib in Mantle Cell Lymphoma, or MCL, by year end, which places the launch one year ahead of Street expectations. The firm raised its price target for shares and keeps an Overweight rating on the name.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use